MEDICAL METHODS OF CORRECTION OF RENAL OSTEODYSTROPHY
https://doi.org/10.14341/osteo2014229-35
Abstract
The article presents a literature review summarizing the contemporary data on the effects of drug therapy on various parameters of renal osteodystrophy: phosphate binders, vitamin D preparations, bisphosphonates, denosumab, and calcimimetics. We discuss the results of pilot study of the efficacy of teriparatide and denosumab on parameters of bone metabolism in patients with chronic kidney disease.
References
1. Рожинская Л.Я., Егшатян Л.В. Патология костной системы при вторичном гиперпаратиреозе у пациентов с терминальной стадией хронической болезни почек на заместительной почечной терапии (гемодиализ). Журнал «Остеопороз и остеопатии». № 1. С 21-25. 2010.
2. Malluche H., Ritz E., Lange H., et al.: Bone histology in incipient and advanced renal failure. Kidney Int 9 : 355 -362, 1976.
3. London G.M., Marty C., Marchais S.J., et al.: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943 -1951, 2004.
4. Adragao T., Ferreira A., Frazao J., et al: Vascular calcifications and bone turnover in hemodialysis patients. Nephrol Dial Transplant 21: 292, 2006.
5. Malluche H.H., Monier-Faugere M.C.: Renal osteodystrophy: What‘s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Neph 65: 235 -242, 2006.
6. Moe S., Drueke T., Cunningham J. et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945 -1953, 2006.
7. Malluche H., Monier-Faugere M.: Hyperphosphatemia: Pharmacologic intervention. Yesterday, today, and tomorrow. Clin Nephrol 54: 309 -317, 2000.
8. Malluche H.H., Monier-Faugere M.C.: Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol 52: 267-277, 1999.
9. Goodman W.G., Goldin J., Kuizon B.D., et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478 -1483, 2000.
10. Malluche H.H., Monier-Faugere M.C.: Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 38: S62 -S67, 1992.
11. Chertow G., Burke S., Raggi P.: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245 -252, 2002.
12. Faugere M., Arnala I., Ritz E., Malluche H.H.: Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 107: 481 -487, 1986.
13. Coburn J., Mischel M., Goodman W.: Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17: 708-711, 1991.
14. Hruska, K., Teitelbaum S.L. Renal osteodystrophy. N Engl J Med. 1995; 333(3): 166-74
15. Zacharias J.M., Fontaine B., Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int.19: 248-252, 1999
16. Fukagawa M., Kazama J.J., Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant. 17 (10): 2-5, 2002
17. Conklin, B.R., and Bourne H.R. Homeostatic signals. Marriage of the flytrap and the serpent. Nature 367: 22-22, 1994
18. Mathew S., Lund R., Strebeck F., et al: Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Neph 18: 122 -130, 2007.
19. Katsumata K., Kusano K., Hirata M., et al: Sevelamer hydrochloride prevents ectopic calcification and renalosteodystrophy in chronic renal failure rats. Kidney Int 64: 441-450, 2003.
20. Ferreira A., Frazao J., Faugere M., et al: Effects of sevelamer hydrochloride and calcium carbonate on bone mineralisation and turnover in haemodialysis patients: A one-year randomised, open-label bone biopsy study [Abstract]. Nephrol Dial Transplant 21: 293, 2006.
21. Raggi P., James G., Burke S.K., et al: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764 -772, 2005.
22. D‘Haese P.C., Spasovski G.B., Sikole A., et al: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl S73 -S78, 2003.
23. Malluche H., Faugere, M.-C., Wang G., Finn W.F.: Lanthanum carbonate and bone: No adverse effects observed after 1 year of treatment in a randomized, comparator-controlled trial [Abstract]. J Am Soc Nephrol 15: 271, 2004.
24. Hartmut H. Malluche, Hanna Mawad. Effects of Treatment of Renal Osteodystrophy on Bone Histology. Clin J Am Soc Nephrol. 3(3): 157-163. 2008.
25. Malluche H., Faugere, M.-C., Wang G.: No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [Abstract]. J Am Soc Nephrol 15: 270A, 2004.
26. Malluche H., Goldstein D., Massry S.: Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 63: 494 -500, 1979.
27. Gonzalez E.A., Sachdeva A., Oliver D.A.: Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. Am J Nephrol 24: 503 -510, 2004.
28. Baker L.R., Abrams L., Roe C.J., еt al: 1,25(OH)2D3 administration in moderate renal failure: A prospective doubleblind trial. Kid Int 35: 661-669, 1989
29. Hamdy N.A., Kanis J.A., Beneton M.N., et al: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358 -363, 1995.
30. Arenas M., Muray S., Amoedo M., et al: A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis. Nefr 26: 226 -233, 2006
31. Goldstein D., Malluche H., Massry S.: Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol 18: 42 -54, 1980.
32. Malluche H., Goldstein D., Massry S.: Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients. Contrib Nephrol 18: 98 -104, 1980.
33. Monier-Faugere M.C., Malluche H.H.: Calcitriol pulse therapy in patients with end-stage renal failure. Curr Opin Nephrol Hypertens 3: 615 -619, 1994.
34. Goodman W., Ramirez J., Belin T., et al: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kid Int 46: 1160 -1166, 1994.
35. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., et al: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the pth/pth-related peptide receptor. Endocr. 142: 1386 -1392, 2001.
36. Langub M.C., Monier-Faugere M.C., et al: Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144: 1135 -1138, 2003.
37. Slatopolsky E., Cozzolino M., Lu Y., et al: Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kid Int 63: 2020 -27, 2003
38. Monier-Faugere M., Geng Z., Friedler R., et al: 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55: 821 -832, 1999.
39. Malluche H., Monier-Faugere M., Wang G., et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Neph. 69: 269-278, 2008
40. Behets G. et al. Poster at ISN Nexus, Copenhagen, Denmark; September 20-23, 2012
41. Spasovski G. et al. Poster at ISN Nexus, Copenhagen, Denmark; September 20-23, 2012
42. Рожинская Л.Я., Егшатян Л.В. Влияние цинакальцета (мимпары) на почечную остеодистрофию у пациентов, находящихся на программном гемодиализе Остеопороз и остеопатии, № 1, стр. 29-33, 2014.
43. Cejka D., Kodras K., Bader T. Treatment of haemodialysis-associated adynamic bone disease with Teriparatide (PTH 1-34): a pilot study. Kidney Blood Press Res. 24; 33(3): 221-226, 2010
44. Torregrosa J.V., Ramos A.M. Use of bisphosphonates in chronic kidney disease. Nefrologia. 30(3): 288-96. 2010.
45. Bergner R.J. Bisphosphonate therapy in renal osteodystrophy-a review. Neph / 26(3): 450-5. 2013
46. Bergner R., Henrich D., Hoffmann M., et al. J Nephrol. Treatment of reduced bone density with ibandronate in dialysis patients. 21(4): 510-6. 2008
47. Amerling R., Harbord N., Pullman J. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 29(3): 293-9. Epub 2010.
48. Charopoulos I. et al. Expert Opin. Drug Saf. 10(2): 205_217, 2011
49. Block G.A., Bone H.G., Fang L. et al: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 27: 1471-1479. 2012;
50. McCormick B.B., Davis J., Burns K.D.: Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis; 60: 626-628. 2012
51. Torregrosa J.V.: Dramatic increase in parathyroid hormone and hypocalcemia after denosumab in a kidney transplanted patient. Clin Kidney J; 6: 122, 2013
52. Ivanov P., Khedr M.: Prolonged hypocalcemia following a single dose of 60 ug denosumab in two patients with CKD4/5 on cinacalcet treatment for tertiary hyperparathyroidism. Clin Kid J 2013
53. Ungprasert O., Cheungpasitporn W., Srivali N,. et al: Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emergency Med; 31: 7561-7562, 2013.
54. Talreja D.B.: Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assessment; 1: 33-36. 2012
55. Agarwal M., Csongradi E., Koch A.C.: Severe symptomatic hypocalcemia after denosumab administration in an end-stage renal disease patient on peritoneal dialysis with controlled secondary hyperparathyroidism. British J Med Medical Research; 3: 1398-1406. 2013
56. Sylvie Dusilová Sulková, Jiří Horáček, Roman Šafránek. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature. Acta Medica (Hradec Kralove). 57(1): 30-3.
Review
For citations:
Egshatyan L.V., Rozhinskaya L.Ya. MEDICAL METHODS OF CORRECTION OF RENAL OSTEODYSTROPHY. Osteoporosis and Bone Diseases. 2014;17(2):29-35. (In Russ.) https://doi.org/10.14341/osteo2014229-35
Views:
3005
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
